Breaking News Instant updates and real-time market news.

CEMP

Cempra

$7.25

0.45 (6.62%)

07:13
11/21/16
11/21
07:13
11/21/16
07:13

Cempra downgraded to Market Perform at Cowen

As reported previously, Cowen analyst Ritu Baral downgraded Cempra to Market Perform from Outperform. The analyst believes its solithromycin approval will come with safety warnings and possibly REMS, limiting commercial adoption to $539M in peak U.S. sales. The downgrade is based on the lack of clarity on the company's path forward. Baral removed her price target on Cempra, which was previously $13.

  • 27

    Dec

  • 28

    Dec

CEMP Cempra
$7.25

0.45 (6.62%)

11/07/16
GABE
11/07/16
DOWNGRADE
GABE
Hold
Cempra downgraded to Hold from Buy at Gabelli
11/08/16
MSCO
11/08/16
DOWNGRADE
Target $5
MSCO
Underweight
Cempra downgraded to Underweight from Overweight at Morgan Stanley
Morgan Stanley analyst Andrew Berens downgraded Cempra to Underweight from Overweight and reduced its price target to $5 from $35 citing numerous FDA safety concerns for Solithera.
11/11/16
NEED
11/11/16
DOWNGRADE
NEED
Hold
Cempra downgraded to Hold from Buy at Needham
11/21/16
COWN
11/21/16
DOWNGRADE
COWN
Market Perform
Cempra downgraded to Market Perform from Outperform at Cowen

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.